Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China. Kailera Therapeutics and Hengrui Pharma have claimed mid-stage victory for ...
Abstract: Over the past decades, the speed and bandwidth of internet systems have dramatically improved. Alongside this, the expansion of cloud server providers, in terms of both price and efficiency, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results